Strategic Investment Advisors MI Sells 174 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Strategic Investment Advisors MI lowered its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 16.9% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 857 shares of the medical research company’s stock after selling 174 shares during the period. Strategic Investment Advisors MI’s holdings in Thermo Fisher Scientific were worth $446,000 as of its most recent filing with the SEC.

A number of other large investors also recently added to or reduced their stakes in TMO. Legacy Investment Solutions LLC purchased a new stake in shares of Thermo Fisher Scientific during the third quarter valued at approximately $26,000. Peterson Financial Group Inc. bought a new stake in Thermo Fisher Scientific in the 3rd quarter worth $27,000. Missouri Trust & Investment Co purchased a new position in shares of Thermo Fisher Scientific in the fourth quarter valued at about $29,000. Endeavor Private Wealth Inc. purchased a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth about $30,000. Finally, Decker Retirement Planning Inc. purchased a new position in Thermo Fisher Scientific during the 4th quarter valued at about $43,000. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $558.12, for a total transaction of $5,581,200.00. Following the transaction, the chief executive officer now owns 33,608 shares in the company, valued at $18,757,296.96. This represents a 22.93 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In the last 90 days, insiders have sold 34,850 shares of company stock worth $19,123,197. Company insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Price Performance

Shares of NYSE TMO opened at $583.43 on Tuesday. The firm has a market cap of $223.16 billion, a P/E ratio of 36.58, a PEG ratio of 3.82 and a beta of 0.76. The company has a 50 day moving average of $533.60 and a 200 day moving average of $569.81. Thermo Fisher Scientific Inc. has a twelve month low of $493.30 and a twelve month high of $627.88. The company has a quick ratio of 1.26, a current ratio of 1.63 and a debt-to-equity ratio of 0.64.

Thermo Fisher Scientific announced that its Board of Directors has initiated a share repurchase plan on Friday, November 15th that allows the company to buyback $4.00 billion in shares. This buyback authorization allows the medical research company to reacquire up to 2% of its shares through open market purchases. Shares buyback plans are generally an indication that the company’s board of directors believes its stock is undervalued.

Thermo Fisher Scientific Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, January 15th. Investors of record on Friday, December 13th were issued a $0.39 dividend. The ex-dividend date of this dividend was Friday, December 13th. This represents a $1.56 annualized dividend and a yield of 0.27%. Thermo Fisher Scientific’s payout ratio is 9.78%.

Analyst Upgrades and Downgrades

TMO has been the topic of several research analyst reports. Barclays reduced their target price on Thermo Fisher Scientific from $620.00 to $610.00 and set an “equal weight” rating on the stock in a research note on Wednesday, October 23rd. Sanford C. Bernstein upgraded shares of Thermo Fisher Scientific from a “market perform” rating to an “outperform” rating and set a $630.00 price objective for the company in a report on Friday, January 10th. Stephens initiated coverage on shares of Thermo Fisher Scientific in a research report on Tuesday, October 1st. They set an “overweight” rating and a $680.00 price target on the stock. StockNews.com upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Tuesday, January 14th. Finally, Morgan Stanley decreased their target price on Thermo Fisher Scientific from $670.00 to $647.00 and set an “overweight” rating for the company in a research report on Monday, January 13th. Four analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $648.95.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.